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years) who started antipsychotic treatment during July 1, 2001 and December 31,
2003. Antipsychotic users were followed for up to six months using an intent-to-
treat approach. Extended Cox proportional hazard regression model stratified on
matched pairs based on the propensity scorewas used to evaluate the comparative
risk of death among users of typical and atypical antipsychotic agents. RESULTS:
There were 84, 162 (42, 081 atypical and 42, 081 typical) users of antipsychotic
agents in the final matched cohort. The unadjusted mortality rate was 11.12% (4,
682) for atypical users and 15.01% (6, 318) for typical users. Results of Cox regression
suggest that, typical users were more likely to die compared to atypical users
[Hazard Ratio (HR) 1.59, 95% Confidence Interval (CI) 1.52-1.66]. The extended Cox
model revealed that the risk of death was greater with typical use during the initial
40 days of treatment [40days: HR 2.00, 1.86-2.15]. The difference in risk persisted
after 40 days of typical antipsychotic use [40-180 days: HR, 1.40, 1.32-1.47].
CONCLUSIONS: The use of typical antipsychotic agents was associated with short-
term and long-term risks of mortality among elderly dual eligible beneficiaries
compared to atypical use. Given the underlying poor health status of dual eligible
beneficiaries, the study findings suggest that the use of typical agents needs to be
optimized in the vulnerable elderly population.
RM4
A SYSTEMATIC REVIEW OF COSTS ASSOCIATED WITH PRESCRIPTION OPIOID
RISKS
Cangelosi MJ, Saunders T, Neumann PJ, Cohen JT
Tufts Medical Center, Boston, MA, USA
OBJECTIVES: The US Food and Drug Administration (FDA) requires drug manufac-
turers to implement Risk Evaluation and Mitigation Strategies (REMS) to ensure
drug benefits outweigh their risks. REMS for opioids target abuse, misuse, addic-
tion, and overdose deaths. This study aims to identify which among these REMS-
designated risk categories contribute most to societal burden, where burden is the
product of prevalence (or rate for death) and per-event cost. This study also exam-
ines opioid diversion risk as a non-REMS secondary outcome.METHODS: Based on
systematic review and meta-analysis, we estimated opioid-related mortality and
prevalence for other outcomes. For outcomes other than death, we estimated
health care costs per occurrence as documented by the Healthcare Cost and Utili-
zation Project (HCUP) dataset. We focused on the value people place on avoiding
death, rather than on the health care resources consumed. As such, we estimated
the cost of each death using the Environmental Protection Agency’s value of a
statistical life (VSL), which reflects willingness to pay to avoid mortality risks.
RESULTS: Excluding populations at high-risk for adverse behaviors, prevalence
rateswere 6% to 38% formisuse, 6% to 15% for abuse, 0.3% to 0.4% for addiction, and
9% to 20% for diversion. Mortality varied widely, ranging from 1 to 108 per 100,000
person years. Treatment costs per occurrence were $8,300 for abuse, $7,400 for
addiction, and $10,000 for diversion. Misuse had no documented treatment costs.
EPA’s VSL is $7.9 million. CONCLUSIONS: Based on prevalence and per occurrence
health care costs, abuse and diversion pose the greatest societal burden, but these
findings require verification due in part to design differences across studies and
differences among populations investigated.
PODIUM SESSION I:
IMPORTANCE OF SELECTION BIAS IN HEALTH CARE RESEARCH
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COMPARISON OF MEDICAL CARE CONSUMPTION BETWEEN DULOXETINE
INITIATORS AND PREGABALIN INITIATORS AMONG FIBROMYALGIA PATIENTS
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OBJECTIVES: To comparemedical care consumption between duloxetine initiators
and pregabalin initiators among fibromyalgia patients.METHODS:Weconducted a
retrospective cohort study based on a US national commercial claims database
(20062009). Fibromyalgia patients who initiated duloxetine or pregabalin in 2008,
age 18 to 64, andmaintained continuous health insurance coverage one year before
and one year after initiation were assigned to duloxetine or pregabalin cohorts
based on their initiated agent. Patients with pill coverage of the agents over last 90
pre-initiation days, with less than 30 supply days of the agents in the follow-up
year, or with a diagnosis of depression, anxiety, DPNP, epilepsy or post-herpetic-
neuralgia before the initiation were excluded. Fibromyalgia-related medical care
consumption (inpatient, outpatient, medication utilization) was compared be-
tween the two cohorts. Bootstrapping and propensity score stratification methods
were used to adjust for distribution bias as well as cross-cohort differences in
demographics, pre-index clinical and economic characteristics, and medication
history. RESULTS: Compared to pregabalin initiators (n4,838), duloxetine initia-
tors (n  3033) had a similar mean initiation age (49 years), female percentage
(89%), percentages of patients using inpatient care (11.6% vs. 11.4%), outpatient
care (100%) andmedications (92.7% vs. 92.8%) in the pre-initiation year. During the
post-initiation year, duloxetine initiators had fewer patients using fibromyalgia-
related inpatient care (2.1% vs. 3.0%, p0.05), fibromyalgia-related outpatient care
(54.0% vs. 64.3%, p0.05), specialty outpatient care (83.7% vs. 89.4%, p0.05), opi-
oids (73.5% vs. 77.1%, p0.05), and non-steroidal anti-inflammatory drugs (38.8%
vs. 41.1%, p0.05) than pregabalin initiators did. They also had fewer inpatient
admissions (0.2 vs. 0.3, p0.05), fibromyalgia-related outpatient claims (4.7 vs. 8.3,
p0.05), specialty outpatient claims (26.1 vs. 30.4, p0.05), and opioid claims (6.0 vs.
7.4, p0.05). CONCLUSIONS: Among fibromyalgia patients, duloxetine initiators
consumed less fibromyalgia-related inpatient, outpatient, and specialty outpatient
care, and had fewer post-initiation claims for opioids.
SB2
COMPARATIVE EFFECTIVENESS OF ON-PUMP AND OFF-PUMP CORONARY
ARTERY BYPASS GRAFTING AMONG ELDERLY PATIENTS – A RETROSPECTIVE
ANALYSIS OF MEDICARE CLAIMS DATA
Datar M, Yang Y, Mahabaleshwarkar R, Bentley JP, Banahan BF
University of Mississippi, University, MS, USA
OBJECTIVES: Conventional (on-pump) coronary artery bypass grafting (CABG) is a
surgical procedure used to restore blood flow to the cardiacmuscle in patientswith
coronary artery disease. Recently, some have suggested that an off-pump CABG
procedure has lesser post-operative morbidity and mortality. Few studies to cor-
roborate this findinghave been conducted in the elderly population. The purpose of
this studywas to compare outcomes associatedwith on-pumpand off-pumpCABG
amongMedicare beneficiaries.METHODS:A retrospective cohort study designwas
used to analyze the 5% national sample of Medicare claims data. Elderly patients
(65 years) who underwent CABG from July 1, 2006 to June 30, 2008 were identified
using ICD-9-CM codes. Outcomes were assessed (using ICD-9-CM codes) following
CABG surgery to December 31, 2008. Outcomes included acute myocardial infarc-
tion (AMI), revascularization such as percutaneous coronary intervention (PCI),
stroke, in-hospital and all-cause mortality. Propensity scores were calculated to
predict the likelihood of each individual receiving on-pump versus off-pump CABG
surgery based on patient demographics and comorbidities (identified from January
1to June 30, 2006) which were then used to match (1:1) patients in the two groups.
Conditional logistic regression was used to compare the outcomes associated with
the two procedures. RESULTS: 2,760 patients (1,380 in each group) met the inclu-
sion criteria. Patients who underwent on-pump CABG had lower odds of in-hospi-
tal mortality (OR: 0.57; 95% CI: 0.39 – 0.83) and all-cause mortality (OR: 0.69; 95% CI:
0.56 – 0.85) as compared to off-pump CABG patients. The procedures were found to
be comparable in terms of clinical outcomes including AMI, PCI and stroke.
CONCLUSIONS: This study found that in-hospital and all-cause mortality associ-
ated with on-pump CABG was lower than off-pump CABG. Further clinical trials
need to be conducted to compare the safety of on-pump versus off-pump CABG
among elderly patients.
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INCREMENTAL CLINICAL AND ECONOMIC BURDEN OF UNCONTROLLED
PARTIAL-ONSET SEIZURES IN A PRIVATELY-INSURED POPULATION
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OBJECTIVES: To assess clinical and economic consequences attributable to loss of
seizure control in privately-insured patients with partial-onset seizures (POS).
METHODS: Health insurance claims from 58 self-insured US companies between
1999 and 2009 were analyzed. Adult patients with POS (ICD-9: 345.4x, 345.5x, or
345.7x) receiving antiepileptic drugs (AED) were selected. A retrospectivematched-
cohort design was used to classify patients into cohorts of “uncontrolled POS” (2
AED therapy changes, followed by 1 epilepsy-related inpatient/ER visit within 1
year; and  1 diagnosis of POS) and “well-controlled POS” (no AED change and no
epilepsy-related inpatient/ER visit). Patients in the well-controlled POS group were
matched 1:1 with uncontrolled POS patients via propensity score matching.
Matched cohorts were compared for healthcare resource use,morbidity, and costs.
Statistical differences between cohorts were assessed using multivariate regres-
sions, adjusted for demographics, baseline AED use, comorbidities and costs.
RESULTS: From 14,377 eligible patients, 279 with uncontrolled POS (mean
age53.4, 55.6% female) were identified and matched 1:1 with well-controlled POS
patients. Compared to the well-controlled POS group, the uncontrolled POS cohort
had significantly more hospitalizations (adjusted rate ratio [ARR] (95% confidence
interval [CI])7.01 [5.97-8.82]), longer hospital stays (ARR (95% CI)10.43 [9.69-
11.23]),more ER visits (ARR (95%CI)4.99 [4.25-5.87]), andmore frequent outpatient
visits (ARR (95% CI)1.58 [1.55-1.62]). Fractures occurred three times more often in
the uncontrolled POS group (ARR (95% CI)3.43 [2.77-4.23]), while head injuries
were twice as frequent (ARR (95%CI)2.28 [2.02-2.56]). The uncontrolled POS group
incurred nearly $15,000 increase in direct healthcare costs (adjusted cost difference
(95% CI)$14,966 [$11,695-$18,944]) versus the well-controlled group. Higher direct
costs for the uncontrolled POS group were observed consistently across prescrip-
tion drug and medical service categories. CONCLUSIONS: Uncontrolled POS was
associated with significantly higher rates of healthcare resource utilization, more
frequent occurrence of fractures and head injuries, and increased direct health
care costs.
SB4
PROPENSITY-SCORE MATCHING (PSM) TO CONTROL FOR SELECTION BIAS IN
“REAL-WORLD” TREATMENT COMPARISONS: A CAUTIONARY TALE
CONCERNING ANTIBIOTIC THERAPY FOR INFECTIOUS DISEASE
Berger A1, Mckinnon PS2, Larson K2, Crompton M2, Hennegan K1, Weber DJ3,
Boening AJ2, Oster G1
1Policy Analysis Inc. (PAI), Brookline, MA, USA, 2Cubist Pharmaceuticals, Inc., Lexington, MA,
USA, 3University of North Carolina School of Medicine, Chapel Hill, NC, USA
OBJECTIVES: In infectious disease, treatment decisions are often influenced by
concerns about antibiotic resistance, which often leads to restriction of newer
agents to sicker patients (i.e., selection bias). PSM is often used to control for this
problem in “real-world” comparisons. We examined the adequacy of PSM in a
“real-world” comparison of vancomycin versus daptomycin as treatment for com-
plicated skin and skin structure infections (cSSSI). METHODS: Using a database
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comprising100 US hospitals, we identified admissions (1/1/2007 - 6/30/2010) with
cSSSI who received initial antibiotic therapy with vancomycin or daptomycin. A
propensity score model was estimated, using demographics, comorbidities, labo-
ratory values, and receipt of vancomycin30 days prior to hospitalization. Vanco-
mycin patients were matched 1:1 to daptomycin patients in stepwise fashion to
minimize the difference in propensity scores for each matched pair (i.e., “greedy”
matching). RESULTS: We identified 347 patients who received daptomycin and
8963 patients who received vancomycin as initial antibiotic therapy for cSSSI. Four
hospitals contributed 54% of daptomycin patients, but only 17% of vancomycin
patients. Daptomycin and vancomycin patients differed significantly in a number
of respects. Only 47.6% of daptomycin patients could be matched to vancomycin
patients (i.e., most patients had nonoverlapping propensity scores). Unmatched
daptomycin patients were older than those in the matched subset (mean age:
57.3yrs vs. 52.3yrs); they alsoweremore likely to have chronic/ulcerative infections
(23% vs. 10%), comorbidities (e.g., diabetes [19% vs. 0%], malnutrition [4% vs. 0%],
alcohol/drug abuse [11% vs. 1%]), and to have been hospitalized previously (63% vs.
39%) (all p0.01). CONCLUSIONS:While PSM is often used to control for selection
bias, the problem of nonoverlapping propensity score distributions is often over-
looked and can adversely impact generalizability. Use of PSM to control for selec-
tion bias in “real-world” comparisons of initial antibiotic therapy for infectious
diseases may be limited; alternate study designs may be needed.
PODIUM SESSION II:
COMPARATIVE EFFECTIVENESS RESEARCH & HEALTH CARE
CE1
COST EFFECTIVENESS TRENDS OF HIGH BUDGET IMPACT DRUGS (2006-2012)
Aggarwal S
Novel Health Strategies, Bethesda, MD, USA
OBJECTIVES: The recently made coverage decisions by UK’s NICE, Scotland’s SMC
and the allocation of $1.1 billion for comparative effectiveness research by the
United States, are strong indicators of trends in pricing and reimbursement that
are likely to be observed in the future. To gain an additional insight into these
trends,we analyzed the cost effectiveness studies for the top twenty highest selling
drugs ($90-100B worldwide sales) METHODS: The Top 20 drugs were selected
based on their worldwide sales. For this analysis, we segmented these drugs into
categories as primary care, specialty, small molecules, biologics, therapy areas and
availability of generic alternatives. We analyzed the cost effectiveness studies that
were published in peer-reviewed journals. Search was conducted using generic
names of the drugs and the phrase cost effectiveness in abstract of the published
study. RESULTS:During 2005-2010, the number of published studies on cost effec-
tiveness have increased by more than 30%. There is a large variability in CERs for
same drugs for different indications, in some cases also varying by biomarkers.
Primary care drugs had lower and less variable CERs than specialty drugs. Varia-
tions also exist in methodology used by different groups in modeling cost effec-
tiveness, especially for time horizon and comparator. Majority of primary care
drugs were modeled for a time horizon of 35-40 years or lifetime to demonstrate
cost effectiveness. CONCLUSIONS: This analysis shows the range, variability and
methods used for calculation of ICER values for these high budget impact drugs and
provides lessons for executives and policy makers.
CE2
COMPARATIVE EFFECTIVENESS OF MONOTHERAPY WITH MOOD STABILIZERS
VERSUS ATYPICAL ANTIPSYCHOTICS FOR THE TREATMENT OF BIPOLAR
DISORDER IN CHILDREN AND ADOLESCENTS: A RETROSPECTIVE CLAIMS-DATA
STUDY
Mehta S1, Patel A2, Aparasu RR2, Perez MO3, Chen H2
1Pharmerit North America, LLC., Bethesda, MD, USA, 2University of Houston, Houston, TX, USA,
3Legacy Community Health Services, Houston, TX, USA
OBJECTIVES:Monotherapy with a mood stabilizer (MS) or second generation anti-
psychotic (SGA) is recommended as the first-line treatment for pediatric bipolar
disorder (PBD). The existing evidence regarding the relative effectiveness of MSs
and SGAs for PBD is predominantly based on short-term studies and does not
adequately address long-term effectiveness. This study compared adherence, per-
sistence, and bipolar-related hospitalization of these treatments during a one-year
observation period. METHODS: The 2003-2007 Medicaid Analytic eXtract data for
four states were used. Bipolar children and adolescents (aged 6-18 years) initiating
treatmentwith SGA orMSmonotherapywere identified. Adherencewasmeasured
using medication possession ratio (MPR) and persistence was measured as time to
medication discontinuation and time to augmentation. Survival Analyseswas con-
ducted to compare time to first bipolar-related hospitalization, time to discontin-
uation and time to augmentation between MS and SGA recipients during a one-
year period after treatment initiation. Heckman’s Two-Step Selection Correction
was used in all survival models to control for treatment selection bias. RESULTS: A
total of 8424 PBD patients were identified. Prescription of SGAs (64.08%) was pre-
dominantly higher than that of MSs (35.92%). The most frequently prescribed SGA
was risperidone, followed by quetiapine and aripiprazole. Divalproex sodium and
oxcarbazepine were most frequently prescribed among MSs. 55% of the patients
initiated on either of the therapeutic category were fully adherent. After correcting
for selection bias, there was no statistically significant difference in the MPR, time
to discontinuation and time to hospitalization between the two study groups. Pa-
tients initiating on SGAs took a longer time to augment (Hazard Ratio: 0.71; 95%CI:
0.57-0.88) with MSs as compared to those who initiated with MSs. CONCLUSIONS:
Although SGAs were prescribed predominantly more than MSs, the two therapeu-
tic classes were comparable in adherence and preventing bipolar related hospital-
ization. SGAs appeared to be slightly better than MSs in terms of time to augmen-
tation.
CE3
GRACE CHECKLIST: RATING THE STRENGTH OF EVIDENCE FOR
OBSERVATIONAL STUDIES OF COMPARATIVE EFFECTIVENESS
Dreyer N1, Velentgas P1, Duddy A1, Westrich KD2, Dubois RW2
1Outcome, A Quintiles Company, Cambridge, MA, USA, 2National Pharmaceutical Council,
Washington, DC, USA
OBJECTIVES: Observational studies are often necessary for assessing the compar-
ative effectiveness of therapeutics in “real-world” settings. The strength of evi-
dence generated by individual studies, however, varies. We describe the develop-
ment of the GRACE Checklist, a tool for rating the quality of observational CER and
assessing whether studies merit consideration for decision making. METHODS: A
checklist was developed based on existing guidelines for the conduct and reporting
of observational studies, including the GRACE Principles, and existing scales for the
inclusion of observational studies in systematic reviews. An external advisory
board reviewed the checklist content and scoring options; majority opinion of the
advisors was used to refine the question items and scoring. The construct validity
of the checklist was measured using two rounds of testing where over 100 volun-
teer testers rated articles, to determine if the checklist can distinguish studies of
known quality. Articles of “known quality” were first extracted from systematic
reviews and then, in the second round, were based on reviews of observational CER
studies by recognized experts. RESULTS: Two domains, internal validity and ap-
plicability, were identified for inclusion with a total of 15 questions. Results and
proposed scoring algorithms will be presented for a categorical assessment of
study quality to determine if studies are 1) of sufficient quality for decision support;
2) sufficiently flawed to make interpretation unreliable; or 3) require additional
consideration. First round testing results showed that subsets of item responses
could yield positive predictive values for identifying high quality studies as high as
0.86, and negative predictive values as high as 0.91. CONCLUSIONS: A validated
checklist to assess the quality of observational CER can help decision makers rec-
ognize strong evidence without substantial advanced training.
CE4
A FRAMEWORK FOR STAKEHOLDER ENGAGEMENT IN COMPARATIVE
EFFECTIVENESS RESEARCH
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OBJECTIVES: Soliciting stakeholder input is becoming commonplace in compara-
tive effectiveness research (CER), yet methods for stakeholder engagement in CER
are evolving. Drawing from CMTP and University of Maryland’s experiences across
a variety of NIH, PCORI, and industry-funded activities as well as previously pub-
lished case analyses, we describe a framework for stakeholder engagement in CER
that standardizes approaches for generating meaningful evidence.METHODS:We
conducted a literature search to explore engagement practices in biomedical sci-
ences, social sciences, and business which included the gray literature. The results
were combined with investigator experience to develop a process framework and
corresponding activities for successful stakeholder engagement. RESULTS:We de-
fined five steps- recruitment, preparation, engagement, dissemination, and evalu-
ation- broadly applicable to stakeholder engagement. Recruitment should begin
with clearly defined expectations for involvement and end with balanced repre-
sentation of stakeholders that meet the needs of the project and disclose conflicts
of interest. Preparing stakeholders for participation in CER requires customized
and relevant background materials. Stakeholder engagement by an experienced
facilitator should guide iterative engagement procedures by using deliberative
methods that ensure a fair, competent and trustworthy process. Dissemination
must document the stakeholders’ input and how this information was incorpo-
rated into decision-making or pathways for implementation. Publications should
also acknowledge stakeholder involvement and contributions. Following dissemi-
nation, evaluation provides both researchers and stakeholders an opportunity to
assess the engagement experience and outcomes, which is necessary for refining
practices for future work. CONCLUSIONS: CER is transitioning toward an interac-
tive framework of stakeholder engagement that enhances the traditional research
paradigm. This processmodel provides a standardmethodology to guide this tran-
sition to stakeholder-based research. This process is adaptable acrossmultiple CER
activities including priority-setting, study design, andmethods guidance aswell as
various therapeutic areas. Further research is needed to refine, evaluate, and apply
this model to ongoing CER activities.
PODIUM SESSION II:
CARDIOVASCULAR DISORDERS OUTCOMES RESEARCH
CV1
DIFFERENCES IN PROCESSES AND OUTCOMES OF CARE IN ELDERLY
HYPERTENSIVE DIABETIC PATIENTS WITH AND WITHOUT DEMENTIA
Chitnis AS, Johnson ML
University of Houston, Houston, TX, USA
OBJECTIVES:Todetermine differences in processes and outcomes of care in elderly
hypertensive diabetic patients with and without dementia.METHODS: This cross-
sectional study was conducted using the household and medical provider compo-
nent files of Medical Expenditure Panel Survey (MEPS) data from 2003, 2005, 2007
and 2009. Hypertensive diabetic patients 50 years of age were identified using
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